Gene therapy for age-related macular degeneration

Nicholas A. Moore, Peter Bracha, Rehan M. Hussain, Nuria Morral, Thomas A. Ciulla

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Introduction: In neovascular age related macular degeneration (nAMD), gene therapy to chronically express anti-vascular endothelial growth factor (VEGF) proteins could ameliorate the treatment burden of chronic intravitreal therapy and improve limited visual outcomes associated with ‘real world’ undertreatment. Areas covered: In this review, the authors assess the evolution of gene therapy for AMD. Adeno-associated virus (AAV) vectors can transduce retinal pigment epithelium; one such early application was a phase I trial of AAV2-delivered pigment epithelium derived factor gene in advanced nAMD. Subsequently, gene therapy for AMD shifted to the investigation of soluble fms-like tyrosine kinase-1 (sFLT-1), an endogenously expressed VEGF inhibitor, binding and neutralizing VEGF-A. After some disappointing results, research has centered on novel vectors, including optimized AAV2, AAV8 and lentivirus, as well as genes encoding other anti-angiogenic proteins, including ranibizumab, aflibercept, angiostatin and endostatin. Also, gene therapy targeting the complement system is being investigated for geographic atrophy due to non-neovascular AMD. Expert opinion: The success of gene therapy for AMD will depend on the selection of the most appropriate therapeutic protein and its level of chronic expression. Future investigations will center on optimizing vector, promoter and delivery methods, and evaluating the risks of the chronic expression of anti-angiogenic or anti-complement proteins.

Original languageEnglish (US)
Pages (from-to)1235-1244
Number of pages10
JournalExpert Opinion on Biological Therapy
Volume17
Issue number10
DOIs
StatePublished - Oct 3 2017

Fingerprint

Gene therapy
Macular Degeneration
Genetic Therapy
Vascular Endothelial Growth Factor A
Geographic Atrophy
Angiogenic Proteins
Angiostatins
Endostatins
Vascular Endothelial Growth Factor Receptor-1
Dependovirus
Lentivirus
Gene encoding
Retinal Pigments
Gene Targeting
Retinal Pigment Epithelium
Expert Testimony
Viruses
Genes
Complement System Proteins
Proteins

Keywords

  • Adeno-associated virus
  • age-related macular degeneration
  • gene therapy
  • retina
  • vascular endothelial growth factor

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Gene therapy for age-related macular degeneration. / Moore, Nicholas A.; Bracha, Peter; Hussain, Rehan M.; Morral, Nuria; Ciulla, Thomas A.

In: Expert Opinion on Biological Therapy, Vol. 17, No. 10, 03.10.2017, p. 1235-1244.

Research output: Contribution to journalReview article

Moore, Nicholas A. ; Bracha, Peter ; Hussain, Rehan M. ; Morral, Nuria ; Ciulla, Thomas A. / Gene therapy for age-related macular degeneration. In: Expert Opinion on Biological Therapy. 2017 ; Vol. 17, No. 10. pp. 1235-1244.
@article{321663fbe632458bb0c9ab338f9d2369,
title = "Gene therapy for age-related macular degeneration",
abstract = "Introduction: In neovascular age related macular degeneration (nAMD), gene therapy to chronically express anti-vascular endothelial growth factor (VEGF) proteins could ameliorate the treatment burden of chronic intravitreal therapy and improve limited visual outcomes associated with ‘real world’ undertreatment. Areas covered: In this review, the authors assess the evolution of gene therapy for AMD. Adeno-associated virus (AAV) vectors can transduce retinal pigment epithelium; one such early application was a phase I trial of AAV2-delivered pigment epithelium derived factor gene in advanced nAMD. Subsequently, gene therapy for AMD shifted to the investigation of soluble fms-like tyrosine kinase-1 (sFLT-1), an endogenously expressed VEGF inhibitor, binding and neutralizing VEGF-A. After some disappointing results, research has centered on novel vectors, including optimized AAV2, AAV8 and lentivirus, as well as genes encoding other anti-angiogenic proteins, including ranibizumab, aflibercept, angiostatin and endostatin. Also, gene therapy targeting the complement system is being investigated for geographic atrophy due to non-neovascular AMD. Expert opinion: The success of gene therapy for AMD will depend on the selection of the most appropriate therapeutic protein and its level of chronic expression. Future investigations will center on optimizing vector, promoter and delivery methods, and evaluating the risks of the chronic expression of anti-angiogenic or anti-complement proteins.",
keywords = "Adeno-associated virus, age-related macular degeneration, gene therapy, retina, vascular endothelial growth factor",
author = "Moore, {Nicholas A.} and Peter Bracha and Hussain, {Rehan M.} and Nuria Morral and Ciulla, {Thomas A.}",
year = "2017",
month = "10",
day = "3",
doi = "10.1080/14712598.2017.1356817",
language = "English (US)",
volume = "17",
pages = "1235--1244",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Gene therapy for age-related macular degeneration

AU - Moore, Nicholas A.

AU - Bracha, Peter

AU - Hussain, Rehan M.

AU - Morral, Nuria

AU - Ciulla, Thomas A.

PY - 2017/10/3

Y1 - 2017/10/3

N2 - Introduction: In neovascular age related macular degeneration (nAMD), gene therapy to chronically express anti-vascular endothelial growth factor (VEGF) proteins could ameliorate the treatment burden of chronic intravitreal therapy and improve limited visual outcomes associated with ‘real world’ undertreatment. Areas covered: In this review, the authors assess the evolution of gene therapy for AMD. Adeno-associated virus (AAV) vectors can transduce retinal pigment epithelium; one such early application was a phase I trial of AAV2-delivered pigment epithelium derived factor gene in advanced nAMD. Subsequently, gene therapy for AMD shifted to the investigation of soluble fms-like tyrosine kinase-1 (sFLT-1), an endogenously expressed VEGF inhibitor, binding and neutralizing VEGF-A. After some disappointing results, research has centered on novel vectors, including optimized AAV2, AAV8 and lentivirus, as well as genes encoding other anti-angiogenic proteins, including ranibizumab, aflibercept, angiostatin and endostatin. Also, gene therapy targeting the complement system is being investigated for geographic atrophy due to non-neovascular AMD. Expert opinion: The success of gene therapy for AMD will depend on the selection of the most appropriate therapeutic protein and its level of chronic expression. Future investigations will center on optimizing vector, promoter and delivery methods, and evaluating the risks of the chronic expression of anti-angiogenic or anti-complement proteins.

AB - Introduction: In neovascular age related macular degeneration (nAMD), gene therapy to chronically express anti-vascular endothelial growth factor (VEGF) proteins could ameliorate the treatment burden of chronic intravitreal therapy and improve limited visual outcomes associated with ‘real world’ undertreatment. Areas covered: In this review, the authors assess the evolution of gene therapy for AMD. Adeno-associated virus (AAV) vectors can transduce retinal pigment epithelium; one such early application was a phase I trial of AAV2-delivered pigment epithelium derived factor gene in advanced nAMD. Subsequently, gene therapy for AMD shifted to the investigation of soluble fms-like tyrosine kinase-1 (sFLT-1), an endogenously expressed VEGF inhibitor, binding and neutralizing VEGF-A. After some disappointing results, research has centered on novel vectors, including optimized AAV2, AAV8 and lentivirus, as well as genes encoding other anti-angiogenic proteins, including ranibizumab, aflibercept, angiostatin and endostatin. Also, gene therapy targeting the complement system is being investigated for geographic atrophy due to non-neovascular AMD. Expert opinion: The success of gene therapy for AMD will depend on the selection of the most appropriate therapeutic protein and its level of chronic expression. Future investigations will center on optimizing vector, promoter and delivery methods, and evaluating the risks of the chronic expression of anti-angiogenic or anti-complement proteins.

KW - Adeno-associated virus

KW - age-related macular degeneration

KW - gene therapy

KW - retina

KW - vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=85028769673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028769673&partnerID=8YFLogxK

U2 - 10.1080/14712598.2017.1356817

DO - 10.1080/14712598.2017.1356817

M3 - Review article

C2 - 28726562

AN - SCOPUS:85028769673

VL - 17

SP - 1235

EP - 1244

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 10

ER -